Atractylenolide I inhibited the development of malignant colorectal cancer cells and enhanced oxaliplatin sensitivity through the PDK1-FoxO1 axis

BACKGROUND: Colorectal cancer (CRC) is a type of ordinary malignancy of the gastrointestinal tract. Atractylenolide I (AT-I) has been shown to inhibit the process of CRC. However, the specific mechanism by which AT-I inhibits CRC is not yet well understood. METHODS: Cell Counting Kit-8 and colony fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ye, Liu, Yi, Cai, Yun, Han, Pingping, Hu, Shan, Cao, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660064/
https://www.ncbi.nlm.nih.gov/pubmed/36388699
http://dx.doi.org/10.21037/jgo-22-910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660064/
https://www.ncbi.nlm.nih.gov/pubmed/36388699
http://dx.doi.org/10.21037/jgo-22-910

Ejemplares similares